|
시장보고서
상품코드
1888572
양성 체위성 현기증 시장 규모, 점유율, 동향 분석 보고서 : 치료제별, 유형별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)Benign Positional Vertigo Market Size, Share & Trends Analysis Report By Therapeutics (Vestibular Function Restoratives, Antivertigo H1 Antihistamines), By Type (Branded, Generic), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033 |
||||||
양성 체위성 현기증 시장 요약
세계의 양성 체위성 현기증 시장 규모는 2024년에 18억 4,000만 달러로 추정되며, 2033년까지 27억 3,000만 달러에 달할 것으로 예측됩니다.
2025-2033년 CAGR 4.5%로 성장할 것으로 예상됩니다. 양성 체위성 현기증 산업은 전정 장애의 유병률 증가, 평형 기능 관련 질환에 대한 인식 개선, 비디오 안진계(VNG) 및 자기공명영상(MRI) 등 진단 도구의 발전에 힘입어 성장하고 있습니다.
내이 기능 장애가 발생하기 쉬운 고령 인구의 증가도 시장 성장을 더욱 촉진하고 있습니다. 항히스타민제, 전정억제제 등 전정재활요법 및 약물 치료의 보급이 수요에 기여하고 있습니다. 또한, 전정기능장애의 메커니즘에 대한 연구가 진전됨에 따라 치료의 접근성과 채택률이 향상될 것으로 기대됩니다.
전정 장애의 증가와 고령 인구의 증가는 다양한 환자군에서 양성 체위성 현기증에 대한 효과적인 치료법에 대한 수요를 견인하고 있습니다. 진단 도구, 비침습적 치료, 가이드 재배치 장치의 발전으로 정확도, 환자 편의성, 임상 결과가 향상되었습니다. 전정기능장애는 노화와 함께 빈번하게 발생하며, 상당수의 위험군을 만들어내고 있습니다. 2023년 7월 'International Journal of Otorhinolaryngology and Head and Neck Surgery'지에 게재된 논문에 따르면, 40세 이상의 노화성 전정기능저하 전체 유병률은 35.4%로 보고되고 있어 집중적인 중재가 필요한 환자층이 매우 많다는 것을 알 수 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 양성 체위성 현기증 시장 변수, 동향, 범위
- 시장 계통 전망
- 상부 시장 전망
- 관련·보조 시장 전망
- 시장 역학
- 양성 체위성 현기증 시장 분석 툴
- 업계 분석 : Porter's Five Forces
- PESTEL 분석
제4장 양성 체위성 현기증 시장 : 치료제 추정·동향 분석
- 양성 체위성 현기증 : 치료제 변동 분석
- 양성 체위성 현기증 시장 규모와 동향 분석(치료법별, 2021-2033년)
- 전정 기능 회복제
- 항현기증 H1 항히스타민제
- 벤조디아제핀계 약제
- 기타
제5장 양성 체위성 현기증 시장 : 유형 추정·동향 분석
- 양성 체위성 현기증 시장 : 유형 변동 분석
- 양성 체위성 현기증 시장 규모와 동향 분석(유형별, 2021-2033년)
- 브랜드
- 제네릭
제6장 양성 체위성 현기증 시장 : 유통 채널 추정·동향 분석
- 양성 체위성 현기증 시장 : 유통 채널 변동 분석
- 양성 체위성 현기증 시장 규모와 동향 분석(유통 채널별, 2021-2033년)
- 원내 약국
- 온라인 약국
- 기타
제7장 양성 체위성 현기증 시장 : 지역 추정·동향 분석
- 지역별 시장 점유율 분석(2024년 및 2033년)
- 지역별 시장 대시보드
- 시장 규모 및 예측 동향 분석, 2021-2033년 :
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제8장 경쟁 구도
- 기업/경쟁 분류
- 전략 매핑
- 2024년의 기업 시장 상황 분석
- 기업 개요/리스트
- Viatris Inc.
- Pfizer Inc.
- Zydus Group
- Prestige Consumer Healthcare Inc
- GSK plc
- Novartis AG
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
Benign Positional Vertigo Market Summary
The global benign positional vertigo market size was estimated at USD 1.84 billion in 2024 and is projected to reach USD 2.73 billion by 2033, growing at a CAGR of 4.5% from 2025 to 2033. The benign positional vertigo industry is driven by the growing prevalence of vestibular disorders, increased awareness of balance-related conditions, and advancements in diagnostic tools such as videonystagmography (VNG) and magnetic resonance imaging (MRI).
Rising geriatric population prone to inner ear dysfunctions further supports market growth. Expanding use of vestibular rehabilitation therapy and pharmacological treatments, including antihistamines and vestibular suppressants, is contributing to demand. In addition, increasing research on vestibular dysfunction mechanisms is expected to enhance treatment accessibility and adoption.
The rise in vestibular disorders and the growing elderly population drive demand for effective treatment options for benign positional vertigo across a wide patient base. Advances in diagnostic tools, non-invasive therapies, and guided repositioning devices have improved accuracy, patient comfort, and clinical outcomes. Vestibular impairments occur frequently with age, creating a substantial population at risk. According to an article published in the International Journal of Otorhinolaryngology and Head and Neck Surgery in July 2023, the overall prevalence of age-related vestibular loss was reported to be 35.4% among individuals aged over 40 years, highlighting the substantial patient pool requiring targeted interventions.
Global Benign Positional Vertigo Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global benign positional vertigo market report based on the therapeutics, type, distribution channel, and region:
- Therapeutics Outlook (Revenue, USD Million, 2021 - 2033)
- Vestibular Function Restoratives
- Antivertigo H1 Antihistamines
- Benzodiazepines
- Others
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Branded
- Generic
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Online Pharmacies
- Other
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1 Market Segmentation & Scope
- 1.2 Segment Definitions
- 1.2.1 Therapeutics
- 1.2.2 Type
- 1.2.3 Distribution Channel
- 1.3 Research Methodology
- 1.4 Information Procurement
- 1.4.1 Purchased database
- 1.4.2 GVR's internal database
- 1.4.3 Secondary sources
- 1.4.4 Primary research
- 1.5 Information or Data Analysis
- 1.5.1 Data analysis models
- 1.6 Market Formulation & Validation
- 1.7 Model Details
- 1.8 List of Secondary Sources
- 1.9 List of Primary Sources
- 1.10 Objectives
Chapter 2 Executive Summary
- 2.1 Market Outlook
- 2.2 Segment Snapshot
- 2.3 Competitive Insights Landscape
Chapter 3 Benign Positional Vertigo Market Variables, Trends & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent market outlook
- 3.1.2 Related/ancillary market outlook.
- 3.2 Market Dynamics
- 3.2.1 Market driver analysis
- 3.2.2 Market restraint analysis
- 3.3 Benign Positional Vertigo Market Analysis Tools
- 3.3.1 Industry Analysis - Porter's
- 3.3.2 PESTEL Analysis
Chapter 4 Benign Positional Vertigo Market: Therapeutics Estimates & Trend Analysis
- 4.1 Segment Dashboard
- 4.2 Benign Positional Vertigo Market Therapeutics Movement Analysis
- 4.3 Benign Positional Vertigo Market Size & Trend Analysis, by Therapeutics, 2021 to 2033 (USD Million)
- 4.4 Vestibular Function Restoratives
- 4.4.1 Vestibular function restoratives market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5 Antivertigo H1 Antihistamines
- 4.5.1 Antivertigo H1 antihistamines market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6 Benzodiazepines
- 4.6.1 Benzodiazepines market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.7 Others
- 4.7.1 Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5 Benign Positional Vertigo Market: Type Estimates & Trend Analysis
- 5.1 Segment Dashboard
- 5.2 Benign Positional Vertigo Market Type Movement Analysis
- 5.3 Benign Positional Vertigo Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 5.4 Branded
- 5.4.1 Branded market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.5 Generic
- 5.5.1 Generic market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6 Benign Positional Vertigo Market: Distribution Channel Estimates & Trend Analysis
- 6.1 Segment Dashboard
- 6.2 Benign Positional Vertigo Market Distribution Channel Movement Analysis
- 6.3 Benign Positional Vertigo Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 6.4 Hospital Pharmacies
- 6.4.1 Hospital pharmacies market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.5 Online Pharmacies
- 6.5.1 Online pharmacies market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.6 Others
- 6.6.1 Others market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7 Benign Positional Vertigo Market: Regional Estimates & Trend Analysis
- 7.1 Regional Market Share Analysis, 2024 & 2033
- 7.2 Regional Market Dashboard
- 7.3 Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 7.4 North America
- 7.4.1 U.S.
- 7.4.1.1 Key country dynamics
- 7.4.1.2 U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4.2 Canada
- 7.4.2.1 Key country dynamics
- 7.4.2.2 Canada market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4.3 Mexico
- 7.4.3.1 Key country dynamics
- 7.4.3.2 Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.4.1 U.S.
- 7.5 Europe
- 7.5.1 UK
- 7.5.1.1 Key country dynamics
- 7.5.1.2 UK market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5.2 Germany
- 7.5.2.1 Key country dynamics
- 7.5.2.2 Germany market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5.3 France
- 7.5.3.1 Key country dynamics
- 7.5.3.2 France market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5.4 Italy
- 7.5.4.1 Key country dynamics
- 7.5.4.2 Italy market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5.5 Spain
- 7.5.5.1 Key country dynamics
- 7.5.5.2 Spain market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5.6 Norway
- 7.5.6.1 Key country dynamics
- 7.5.6.2 Norway market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5.7 Sweden
- 7.5.7.1 Key country dynamics
- 7.5.7.2 Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5.8 Denmark
- 7.5.8.1 Key country dynamics
- 7.5.8.2 Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5.1 UK
- 7.6 Asia Pacific
- 7.6.1 Japan
- 7.6.1.1 Key country dynamics
- 7.6.1.2 Japan market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.6.2 China
- 7.6.2.1 Key country dynamics
- 7.6.2.2 China market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.6.3 India
- 7.6.3.1 Key country dynamics
- 7.6.3.2 India market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.6.4 Australia
- 7.6.4.1 Key country dynamics
- 7.6.4.2 Australia market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.6.5 South Korea
- 7.6.5.1 Key country dynamics
- 7.6.5.2 South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.6.6 Thailand
- 7.6.6.1 Key country dynamics
- 7.6.6.2 Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.6.1 Japan
- 7.7 Latin America
- 7.7.1 Brazil
- 7.7.1.1 Key country dynamics
- 7.7.1.2 Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.7.2 Argentina
- 7.7.2.1 Key country dynamics
- 7.7.2.2 Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.7.1 Brazil
- 7.8 MEA
- 7.8.1 South Africa
- 7.8.1.1 Key country dynamics
- 7.8.1.2 South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.8.2 Saudi Arabia
- 7.8.2.1 Key country dynamics
- 7.8.2.2 Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.8.3 UAE
- 7.8.3.1 Key country dynamics
- 7.8.3.2 UAE market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.8.4 Kuwait
- 7.8.4.1 Key country dynamics
- 7.8.4.2 Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.8.1 South Africa
Chapter 8 Competitive Landscape
- 8.1 Company/Competition Categorization
- 8.2 Strategy Mapping
- 8.3 Company Market Position Analysis, 2024
- 8.4 Company Profiles/Listing
- 8.4.1 Viatris Inc.
- 8.4.1.1 Company overview
- 8.4.1.2 Financial performance
- 8.4.1.3 Product benchmarking
- 8.4.1.4 Strategic initiatives
- 8.4.2 Pfizer Inc.
- 8.4.2.1 Company overview
- 8.4.2.2 Financial performance
- 8.4.2.3 Product benchmarking
- 8.4.2.4 Strategic initiatives
- 8.4.3 Zydus Group
- 8.4.3.1 Company overview
- 8.4.3.2 Financial performance
- 8.4.3.3 Product benchmarking
- 8.4.3.4 Strategic initiatives
- 8.4.4 Prestige Consumer Healthcare Inc
- 8.4.4.1 Company overview
- 8.4.4.2 Financial performance
- 8.4.4.3 Product benchmarking
- 8.4.4.4 Strategic initiatives
- 8.4.5 GSK plc
- 8.4.5.1 Company overview
- 8.4.5.2 Financial performance
- 8.4.5.3 Product benchmarking
- 8.4.5.4 Strategic initiatives
- 8.4.6 Novartis AG
- 8.4.6.1 Company overview
- 8.4.6.2 Financial performance
- 8.4.6.3 Product benchmarking
- 8.4.6.4 Strategic initiatives
- 8.4.7 Johnson & Johnson
- 8.4.7.1 Company overview
- 8.4.7.2 Financial performance
- 8.4.7.3 Product benchmarking
- 8.4.7.4 Strategic initiatives
- 8.4.8 Teva Pharmaceutical Industries Ltd.
- 8.4.8.1 Company overview
- 8.4.8.2 Financial performance
- 8.4.8.3 Product benchmarking
- 8.4.8.4 Strategic initiatives
- 8.4.9 Sun Pharmaceutical Industries Ltd.
- 8.4.9.1 Company overview
- 8.4.9.2 Financial performance
- 8.4.9.3 Product benchmarking
- 8.4.9.4 Strategic initiatives
- 8.4.1 Viatris Inc.
(주말 및 공휴일 제외)
